Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure

Tingting DENG; Li LI; Ying GUAN; Xueyan LUO; Kun QIN; Min LIU

doi:10.3969/j.issn.1001-5256.2022.10.028

Volume 38 Issue 10

Oct. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(10): 2346-2351

PDF( 1789 KB)

Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2022.10.028

Tingting DENG¹,
Li LI^{1, 2
,
,
,},
Ying GUAN¹,
Xueyan LUO¹,
Kun QIN¹,
Min LIU¹

1.
The First Clinical Institute, Zunyi Medical University, Zunyi, Guizhou 563000, China
2.
Department of General Medicine, Qianxinan Affiliated Hospital of Zunyi Medical University, Xingyi, Guizhou 562400, China

Research funding:

Special Research on Clinical Topics for Guizhou Provincial Governor's Funds (Qian Province Specialized Cooperation [2012] No. 113);

Science and Technology Plan of Guizhou Province (Qian Kehe SY [2013] No. 3029)

More Information

Corresponding author: LI Li, 1444522659@qq.com(ORCID: 0000-0003-2664-3832)
Received Date: 2022-03-01
Accepted Date: 2022-04-08
Published Date: 2022-10-20

Abstract

Abstract

Acute-on-chronic liver failure (ACLF) is a clinical syndrome with short-term rapid deterioration, multiple organ failure, and high mortality and has become a research hotspot in the field of severe liver diseases. Early, accurate, and quick judgment of clinical prognosis and timely intervention of disease progression are of great significance for improving disease outcome. This article summarizes the inflammation-related prognostic markers for HBV-related ACLF found in recent years, so as to improve the existing prognostic indicators and provide more basis for evaluating the prognosis of ACLF patients by clinicians.
- Hepatitis B Virus,
- Acute-On-Chronic Liver Failure,
- Biomarkers,
- Prognosis

FullText(HTML)

References(43)

References

[1]	SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update[J]. Hepatol Int, 2019, 13(4): 353-390. DOI: 10.1007/s12072-019-09946-3.
[2]	CHEN JJ, FAN LX, LI LJ. Interpretation of Diagnostic and treatment guidelines for liver failure (2018 edition)[J]. Chin J Clinicians, 2020, 48(11): 1279-1282. DOI: 10.3969/j.issn.2095-8552.2020.11.005. 陈佳佳, 范林骁, 李兰娟. 《肝衰竭诊治指南(2018版)》指南解读[J]. 中国临床医生杂志, 2020, 48(11): 1279-1282. DOI: 10.3969/j.issn.2095-8552.2020.11.005.
[3]	ZHANG H, JIA L, Yao SW, et al. Value of MELD combined with serum sodium concentration in predicting the short-term outcome of patients with HBV-related acute-on-chronic liver failure in China: A meta-analysis[J]. J Clin Hepatol, 2018, 34(9): 1950-1955. DOI: 10.3969/j.issn.1001-5256.2018.09.024. 张辉, 贾雷, 姚士伟, 等. MELD-Na评分对我国HBV相关慢加急性肝衰竭短期预后预测价值的Meta分析[J]. 临床肝胆病杂志, 2018, 34(9): 1950-1955. DOI: 10.3969/j.issn.1001-5256.2018.09.024.
[4]	LI ZL, TONG XJ, TIAN WW, et al. Expression of interleukin-26 in patients with hepatitis B virus-related acute-on-chronic liver failure and its clinical significance[J]. Clin J Med Offic, 2020, 48(12): 1492-1493, 1496. DOI: 10.16680/j.1671-3826.2020.12.39. 李增莲, 仝晓净, 田稳稳, 等. 白细胞介素26在乙型肝炎病毒相关慢加急性肝衰竭患者中表达及临床意义[J]. 临床军医杂志, 2020, 48(12): 1492-1493, 1496. DOI: 10.16680/j.1671-3826.2020.12.39.
[5]	WANG TS, WANG N, ZHANG RZ, et al. Role of immune response and inflammatory injury in the pathogenesis of liver failure[J]. J Clin Hepatol, 2020, 36(6): 1415-1419. DOI: 10.3969/j.issn.1001-5256.2020.06.050. 王挺帅, 王娜, 张荣臻, 等. 免疫反应与炎症损伤在肝衰竭发病机制中的作用[J]. 临床肝胆病杂志, 2020, 36(6): 1415-1419. DOI: 10.3969/j.issn.1001-5256.2020.06.050.
[6]	SUN J, GUO H, YU X, et al. A neutrophil-to-lymphocyte ratio-based prognostic model to predict mortality in patients with HBV-related acute-on-chronic liver failure[J]. BMC Gastroenterol, 2021, 21(1): 422. DOI: 10.1186/s12876-021-02007-w.
[7]	BERNSMEIER C, CAVAZZA A, FATOUROU EM, et al. Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure[J]. Aliment Pharmacol Ther, 2020, 52(5): 855-865. DOI: 10.1111/apt.15932.
[8]	BAO S, ZHENG J, LI N, et al. Role of interleukin-23 in monocyte-derived dendritic cells of HBV-related acute-on-chronic liver failure and its correlation with the severity of liver damage[J]. Clin Res Hepatol Gastroenterol, 2017, 41(2): 147-155. DOI: 10.1016/j.clinre.2016.10.005.
[9]	MO R, WANG P, LAI R, et al. Persistently elevated circulating Th22 reversely correlates with prognosis in HBV-related acute-on-chronic liver failure[J]. J Gastroenterol Hepatol, 2017, 32(3): 677-686. DOI: 10.1111/jgh.13537.
[10]	SCHWARZKOPF K, RVSCHENBAUM S, BARAT S, et al. IL-22 and IL-22-binding protein are associated with development of and mortality from acute-on-chronic liver failure[J]. Hepatol Commun, 2019, 3(3): 392-405. DOI: 10.1002/hep4.1303.
[11]	XIANG X, FENG D, HWANG S, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice[J]. J Hepatol, 2020, 72(4): 736-745. DOI: 10.1016/j.jhep.2019.11.013.
[12]	DU XX, SHI Y, YANG Y, et al. DAMP molecular IL-33 augments monocytic inflammatory storm in hepatitis B-precipitated acute-on-chronic liver failure[J]. Liver Int, 2018, 38(2): 229-238. DOI: 10.1111/liv.13503.
[13]	YUAN W, MEI X, ZHANG YY, et al. High expression of interleukin-33/st2 predicts the progression and poor prognosis in chronic hepatitis B patients with hepatic flare[J]. Am J Med Sci, 2020, 360(6): 656-661. DOI: 10.1016/j.amjms.2020.06.023.
[14]	WU ZB, ZHENG YB, WANG K, et al. Plasma interleukin-6 level: A potential prognostic indicator of emergent HBV-associated ACLF[J]. Can J Gastroenterol Hepatol, 2021, 2021: 5545181. DOI: 10.1155/2021/5545181.
[15]	ZHOU C, ZHANG N, HE TT, et al. High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure[J]. World J Gastroenterol, 2020, 26(30): 4479-4488. DOI: 10.3748/wjg.v26.i30.4479.
[16]	HE Y, FENG D, HWANG S, et al. Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IκBζ target genes in hepatocytes[J]. J Hepatol, 2021, 75(1): 163-176. DOI: 10.1016/j.jhep.2021.02.004.
[17]	LIU Y, MENG X, WANG C, et al. Interleukin-18 plays a positive feedback activity to natural killer-like B cells in hepatitis B virus-associated acute-on-chronic liver failure[J]. Viral Immunol, 2022, 35(1): 50-59. DOI: 10.1089/vim.2021.0164.
[18]	SHEN G, SUN S, HUANG J, et al. Dynamic changes of T cell receptor repertoires in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Hepatol Int, 2020, 14(1): 47-56. DOI: 10.1007/s12072-019-10008-x.
[19]	LI J, HU CH, CHEN Y, et al. Characteristics of peripheral lymphocyte subsets in patients with acute-on-chronic liver failure associated with hepatitis B[J]. Front Med (Lausanne), 2021, 8: 689865. DOI: 10.3389/fmed.2021.689865.
[20]	ZHANG GL, ZHANG T, ZHAO QY, et al. Increased IL-17-producing CD8⁺ T cell frequency predicts short-term mortality in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Ther Clin Risk Manag, 2018, 14: 2127-2136. DOI: 10.2147/TCRM.S184809.
[21]	ZHANG GL, ZHANG T, ZHAO QY, et al. Th17 cells over 5.9% at admission indicate poor prognosis in patients with HBV-related acute-on-chronic liver failure[J]. Medicine (Baltimore), 2018, 97(40): e12656. DOI: 10.1097/MD.0000000000012656.
[22]	TAN NH, CHEN B, PENG J, et al. Treg/Th17 cell balance in patients with hepatitis B virus-related acute-on-chronic liver failure at different disease stages[J]. Biomed Res Int, 2021, 2021: 9140602. DOI: 10.1155/2021/9140602.
[23]	LU YY, XIN JJ, DING WC, et al. Expression and diagnostic value of macrophage inflammatory protein-3α in patients with hepatitis B-related acute-on-chronic liver failure[J]. Chin J Hepatol, 2021, 29(12): 1156-1163. DOI: 10.3760/cma.j.cn501113-20210809-00386. 卢莺燕, 辛娇娇, 丁文超, 等. 巨噬细胞炎性蛋白-3α在乙型肝炎相关慢加急性肝衰竭患者中的表达及其诊断价值[J]. 中华肝脏病杂志, 2021, 29(12) : 1156-1163. DOI: 10.3760/cma.j.cn501113-20210809-00386.
[24]	WANG XL, CHEN XJ, YE HH, et al. Association of mRNA expression level of IP-10 in peripheral blood mononuclear cells with HBV-associated acute-on-chronic liver failure and its prognosis[J]. J Huazhong Univ Sci Technolog Med Sci, 2017, 37(5): 755-760. DOI: 10.1007/s11596-017-1800-2.
[25]	XIAO L, TANG S, ZHANG L, et al. Serum CXCL1 is a prognostic factor for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Front Med (Lausanne), 2021, 8: 657076. DOI: 10.3389/fmed.2021.657076.
[26]	ZHANG DN, LIU Y, LI X, et al. Imbalance between soluble and membrane-bound CD100 regulates monocytes activity in hepatitis B virus-associated acute-on-chronic liver failure[J]. Viral Immunol, 2021, 34(4): 273-283. DOI: 10.1089/vim.2020.0311.
[27]	ZHAO R, WU W, ZHOU Z, et al. Prognostic utility of novel biomarkers in acute-on-chronic liver failure (ACLF) associated with hepatitis B: A multicenter prospective study[J]. Hepatol Res, 2019, 49(1): 42-50. DOI: 10.1111/hepr.13251.
[28]	GRØNBAEK H, MØLLER HJ, SALIBA F, et al. Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation[J]. J Gastroenterol Hepatol, 2021, 36(1): 240-248. DOI: 10.1111/jgh.15125.
[29]	JIA Y, MA L, WANG Y, et al. NLRP3 inflammasome and related cytokines reflect the immune status of patients with HBV-ACLF[J]. Mol Immunol, 2020, 120: 179-186. DOI: 10.1016/j.molimm.2020.01.011.
[30]	LI Z, JIANG J. The NLRP3 inflammasome mediates liver failure by activating procaspase-1 and pro-IL-1 β and regulating downstream CD40-CD40L signaling[J]. J Int Med Res, 2021, 49(9): 3000605211036845. DOI: 10.1177/03000605211036845.
[31]	BAI L, KONG M, DUAN Z, et al. M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis[J]. Cell Death Dis, 2021, 12(1): 93. DOI: 10.1038/s41419-020-03378-w.
[32]	ZHANG GL, ZHANG T, YE YN, et al. Complement factor 3 could be an independent risk factor for mortality in patients with HBV related acute-on-chronic liver failure[J]. Biomed Res Int, 2016, 2016: 3524842. DOI: 10.1155/2016/3524842.
[33]	LI Q, LU Q, ZHU MQ, et al. Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure[J]. BMC Gastroenterol, 2020, 20(1): 106. DOI: 10.1186/s12876-020-01258-3.
[34]	ZHOU N, WANG K, FANG S, et al. Discovery of a potential plasma protein biomarker panel for acute-on-chronic liver failure induced by hepatitis B virus[J]. Front Physiol, 2017, 8: 1009. DOI: 10.3389/fphys.2017.01009.
[35]	LI TP, GUAN SH, WANG Q, et al. Soluble mannose receptor as a predictor of prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. World J Gastroenterol, 2019, 25(37): 5667-5675. DOI: 10.3748/wjg.v25.i37.5667.
[36]	WANG K, ZHANG Z, MO ZS, et al. Gut microbiota as prognosis markers for patients with HBV-related acute-on-chronic liver failure[J]. Gut Microbes, 2021, 13(1): 1-15. DOI: 10.1080/19490976.2021.1921925.
[37]	MA S, XIE Z, ZHANG L, et al. Identification of a potential miRNA-mRNA regulatory network associated with the prognosis of HBV-ACLF[J]. Front Mol Biosci, 2021, 8: 657631. DOI: 10.3389/fmolb.2021.657631.
[38]	CISILOTTO J, DO AMARAL AE, ROSOLEN D, et al. MicroRNA profiles in serum samples from acute-on-chronic liver failure patients and miR-25-3p as a potential biomarker for survival prediction[J]. Sci Rep, 2020, 10(1): 100. DOI: 10.1038/s41598-019-56630-5.
[39]	LIU H, LI Y, GAO F, et al. Serum clusterin: A potential marker for assessing the clinical severity and short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Dis Markers, 2020, 2020: 8814841. DOI: 10.1155/2020/8814841.
[40]	WU D, ZHANG S, XIE Z, et al. Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure[J]. J Clin Invest, 2020, 130(4): 2069-2080. DOI: 10.1172/JCI130197.
[41]	SUN Z, LIU X, WU D, et al. Circulating proteomic panels for diagnosis and risk stratification of acute-on-chronic liver failure in patients with viral hepatitis B[J]. Theranostics, 2019, 9(4): 1200-1214. DOI: 10.7150/thno.31991.
[42]	JUANOLA A, GRAUPERA I, ELIA C, et al. Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis[J]. J Hepatol, 2022, 76(1): 107-114. DOI: 10.1016/j.jhep.2021.08.031.
[43]	LI J, LIANG X, JIANG J, et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF[J]. Gut, 2022, 71(1): 163-175. DOI: 10.1136/gutjnl-2020-323395.

Relative Articles

[1]	Zexin HU, Jintao HUANG, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Current status and prospects of transarterial chemoembolization and its combined regimens in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(1): 175-180. doi: 10.12449/JCH240129
[2]	Wencong DAI, Mengya ZANG, Guosheng YUAN, Qi LI, Rong LI, Wenli LI, Shuyu DONG, Jinzhang CHEN. Efficacy of hepatic arterial infusion chemotherapy and its multimodality therapeutic regimens in treatment of patients with advanced hepatocellular carcinoma and related prognostic factors[J]. Journal of Clinical Hepatology, 2023, 39(7): 1592-1599. doi: 10.3969/j.issn.1001-5256.2023.07.013
[3]	Xiufeng LIU, Jue ZHANG, Lin YAO, Chaoxu YANG. Advances in targeted therapy combined with immunotherapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 992-997. doi: 10.3969/j.issn.1001-5256.2022.05.004
[4]	Sirou LI, Yuanlong ZHOU, Keliang LIU, Zhibo LIANG, Jinghua LI. Conversion therapy for massive hepatocellular carcinoma: A case report[J]. Journal of Clinical Hepatology, 2022, 38(7): 1612-1615. doi: 10.3969/j.issn.1001-5256.2022.07.028
[5]	Kailing XIE, Feng XU. Mechanism of action of Huaier granules in treatment of hepatocellular carcinoma and advances in its clinical application[J]. Journal of Clinical Hepatology, 2022, 38(3): 676-681. doi: 10.3969/j.issn.1001-5256.2022.03.038
[6]	Mengkui HAN, Jin LI, Xiaohua YANG. Function and regulatory mechanism of T lymphocytes in tumor immune microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2621-2626. doi: 10.3969/j.issn.1001-5256.2022.11.037
[7]	Zhiyuan HOU, Yuan LIU, Chaoran YANG, Jisen ZHAO, Shujie CHENG. Current research status and prospect of circulating tumor DNA in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2616-2620. doi: 10.3969/j.issn.1001-5256.2022.11.036
[8]	Zhiyuan YU, Shiyu YANG, Jiaqi LI, Yan SUN. Current developmental status of non-surgical treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1205-1207. doi: 10.3969/j.issn.1001-5256.2021.05.048
[9]	Tianle GONG, Ping YUE, Jun YAN, Xun LI. Adjuvant therapies after surgery for hepatocellular carcinoma with microvascular invasion[J]. Journal of Clinical Hepatology, 2021, 37(3): 685-688. doi: 10.3969/j.issn.1001-5256.2021.03.037
[10]	Guoxiang CHEN, Mo ZHOU, Sheng CHEN, Yuan WANG, Yuanlong ZHOU, Jihong YANG. Mechanism of action of non-coding RNA in sorafenib resistance in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(3): 699-703. doi: 10.3969/j.issn.1001-5256.2021.03.040
[11]	Shisi LI, Zhitang GUO, Zhangbin CHEN, Yishan TENG. Research advances in systemic therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(12): 2943-2946. doi: 10.3969/j.issn.1001-5256.2021.12.044
[12]	Yanmei ZOU, Xianglin YUAN. Application value of immunotherapy in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1758-1760. doi: 10.3969/j.issn.1001-5256.2021.08.004
[13]	Ningning ZHANG, Wei LU. Targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1753-1757. doi: 10.3969/j.issn.1001-5256.2021.08.003
[14]	Wang XiaoYun, Li LinFeng, Guo Quan, Ceng YiLan, Li HaiYang, Du YingRong, Chen Gang, Liang YueDong, Lu YinYing. Development and enlightenment of intelligentized diagnostic and therapeutic mode for hepatobiliary tumors[J]. Journal of Clinical Hepatology, 2019, 35(10): 2360-2364. doi: 10.3969/j.issn.1001-5256.2019.10.051
[15]	Shang ZhiYin, Yang JingMao, Chen LiPing, Liu Min, Cheng Kai, Li YaoHua, Ai YingChun, Cheng JiLin. Changes in gastrointestinal structure and function caused by cirrhotic portal hypertension and related clinical manifestations[J]. Journal of Clinical Hepatology, 2017, 33(2): 354-358. doi: 10.3969/j.issn.1001-5256.2017.02.034
[16]	Xu ZhengGuo, Zhao YongBing, Zheng YuanYu, Liu En, Yang ShiMing. Association between portal vein pressure drop gradient after transjugular intrahepatic portosystemic shunt and clinical prognosis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2016.12.019
[17]	Shi XiaoJu, Lyu GuoYue, Zhang Ping, Du XiaoHong, Wang GuangYi. Postoperative application of multidisciplinary treatment in patients with hepatobiliary and pancreatic malignancies[J]. Journal of Clinical Hepatology, 2015, 31(11): 1886-1888. doi: 10.3969/j.issn.1001-5256.2015.11.028
[18]	Society of Liver Cancer, Guangdong Provincial Anti-cancer Association. Strategy and method of multi-disciplinary comprehensive treatment of liver cancer-consensus of experts in Guangdong, China (2)[J]. Journal of Clinical Hepatology, 2014, 30(11): 1116-1119. doi: 10.3969/j.issn.1001-5256.2014.11.005
[19]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[20]	Wang JiYao. Importance of detecting portal hypertension in liver cirrhosis patients: theory, research tools, and clinical applications[J]. Journal of Clinical Hepatology, 2012, 28(9): 642-643.

Supplements(0)

Cited By

Cited by

Periodical cited type(20)

1.	秦鹏，李树森，刘皓，吴广迎. 胃冠状静脉栓塞术在门脉高压性上消化道出血经颈静脉肝内门腔静脉分流术患者中的临床疗效. 血管与腔内血管外科杂志. 2022(09): 1130-1134 .
2.	高绍，王宏亮，聂春晖，张岳林，周坦洋，余子牛，杨月，孙军辉. 对比TIPS联合胃冠状静脉栓塞术与单独TIPS治疗肝硬化门静脉高压伴上消化道出血的中远期疗效：Meta分析. 中国介入影像与治疗学. 2022(11): 673-677 .
3.	张大维，吴东辉，孙兴安. TIPS对肝硬化并发上消化道出血患者近期肝肾功能和远期疗效的影响. 当代医学. 2021(35): 129-130 .
4.	林纲毅，马洺远，蔡宗洋. 超声引导下门静脉穿刺导引经颈静脉肝内门体分流术联合曲张静脉栓塞治疗食管胃底静脉曲张破裂出血的临床效果. 中国当代医药. 2020(07): 113-116 .
5.	王宁，林芳明，吕明. TIPS联合GCVE用于门静脉高压并发上消化道大出血的应用价值. 肝脏. 2020(09): 952-954 .
6.	韩志强. 肝硬化上消化道出血37例外科临床治疗效果观察. 世界最新医学信息文摘. 2019(05): 95+102 .
7.	张明礼. PTVE联合PSE治疗肝硬化门脉高压并上消化道出血的观察. 实用中西医结合临床. 2019(05): 24-26 .
8.	孙允涛. 肝硬化门静脉高压并发上消化道出血的相关危险因素分析. 中国民康医学. 2019(10): 81-83 .
9.	孙巧玉，赖雪珍，河源媛. 门脉高压合并上消化道出血采用PTVE联合PSE手术的效果分析. 现代消化及介入诊疗. 2019(08): 837-841+846 .
10.	杨荣焕. TIPS和PTVE介入方法治疗肝硬化门静脉高压引起的上消化道出血的优劣差异. 黑龙江医学. 2019(09): 1012-1013+1016 .
11.	武和平. 不同介入途径胃冠状静脉栓塞术治疗肝硬化门静脉高压出血的临床疗效观察. 现代消化及介入诊疗. 2018(02): 208-210 .
12.	李广忠. 分析肝硬化门脉高压症下食管静脉曲张破裂出血的危险因素. 智慧健康. 2018(07): 91-92+126 .
13.	李贤圣，董勤勇，张乐，夏侨，贺军. 经颈静脉门静脉分流术介入治疗门静脉高压引起上消化道出血的疗效分析. 浙江创伤外科. 2018(02): 272-273 .
14.	赵晓飞，林栋栋，李宁，臧运金，郭庆良，武聚山. 门静脉高压患者脾切断流术后曲张静脉再出血的危险因素分析. 临床肝胆病杂志. 2018(10): 2182-2185 . 本站查看
15.	吴笋. 经颈静脉肝内门体静脉分流术加胃冠状静脉栓塞术治疗门脉高压症初探. 现代医用影像学. 2018(05): 1522-1523+1528 .
16.	田广俊，池晓玲，常钢，孟凡喆，曹敏玲，黎英贤，徐浩祥，梁宏才，赵朋涛，吴晓菊，萧焕明. 中药灌肠防治TIPS治疗肝硬化门静脉高压伴上消化道出血术后肝性脑病临床观察. 新中医. 2018(12): 87-91 .
17.	樊春燕，叶晓丽，戴晓婷，吴宇清. 肝硬化门静脉高压并发上消化道出血的相关性分析研究. 血管与腔内血管外科杂志. 2018(05): 381-385 .
18.	彭虹. 肝硬化门静脉高压并发上消化道出血的相关危险因素分析. 中国继续医学教育. 2017(31): 58-59 .
19.	张志勇. 不同手术方案治疗肝硬化门脉高压症的临床对比. 临床医药文献电子杂志. 2017(46): 8924-8925 .
20.	向平，张川，张亮科，唐瑞强，叶继彬. 1例上消化道出血病人护理体会. 世界最新医学信息文摘. 2016(14): 247 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (609) PDF downloads(78)

Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2022.10.028